Last Updated : March 11, 2021
Details
FilesProject Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1340-000
Question
- What is the clinical effectiveness of onabotulinum toxin A (Botox) in the treatment of spasticity associated with multiple sclerosis?
- What is the cost-effectiveness of onabotulinum toxin A (Botox) in the treatment of spasticity associated with multiple sclerosis?
- What are the evidence-based guidelines for the use of onabotulinum toxin A (Botox) in a treatment regimen for spasticity associated with multiple sclerosis?
Key Message
Evidence-based clinical practice guidelines recommend the use of botulinum toxin (which includes onabotulinum toxin A [Botox]) to treat spasticity caused by multiple sclerosis. There is a lack of recent evidence regarding the clinical and cost-effectiveness of Botox as a treatment for spasticity caused by multiple sclerosis; thus, there is a need for well-designed studies on this topic.
Files
Last Updated : March 11, 2021